Transient lesions of the splenium of the corpus callosum following rapid withdrawal of levetiracetam

Sawagashira, Ryo; Narita, Hisashi; Hashimoto, Naoki; Kurita, Tsugiko; Nakagawa, Shin; Saitoh, Takuya; Kusumi, Ichiro

doi:10.1684/epd.2017.0923

Cited by 6 publications

(8 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1. Axial diffusion-weighted magnetic resonance images (DWI) demonstrate high signal intensity on the sple nium of the corpus callosum on day 2 of hospitalization diverse clinical conditions including the use of antiepileptic drugs, hypoglycaemia, and are related to migraine with aura in children (10)(11)(12). Recent case reports illustrate that rotavirus RNA may be found in the cerebrospinal fluid (CSF) of patients with gastroenteritis and neurological symptoms (13,14).…”

Section: Discussionmentioning

confidence: 99%

Rotavirus-associated seizures and reversible corpus callosum lesion

Laizāne¹,

Smane²,

Nokalna³

et al. 2019

AML

View full text Add to dashboard Cite

Rotavirus is a non-enveloped double-stranded RNA virus that causes severe gastroenteritis in children, but complications are rarely reported. Some reports have shown that rotavirus can induce diverse complications of the central nervous system, such as seizures, encephalopathy with a reversible splenial lesion, encephalitis, cerebral white matter abnormalities, and cerebellitis. Here, we present a 2-year-old patient with seizures, who had an isolated splenial lesion in the corpus callosum on neuroimaging, and the rotavirus antigen detected in faeces.

show abstract

Section: Discussionmentioning

confidence: 99%

Rotavirus-associated seizures and reversible corpus callosum lesion

Laizāne¹,

Smane²,

Nokalna³

et al. 2019

AML

View full text Add to dashboard Cite

show abstract

“…Levetiracetam was suspected to play a role in the onset of RESLES in case 7, to the best of our knowledge, this is the first report of levetiracetam to be associated with the etiology of RESLES, while the withdrawal of levetiracetam has been previously reported to cause RESLES (34). After carbamazepine treatment was given because of vestibular paroxysmia in case 12, an SCC lesion was discovered 34 days later after carbamazepine treatment.…”

Section: Discussionmentioning

confidence: 65%

“…Valproate (26), oxcarbazepine (5,33), topiramate (30), levetiracetam (34), phenytoin (3,42), carbamazepine (72) Oxcarbazepine (33) Autoimmune disease…”

Section: Discussionmentioning

confidence: 99%

“…Certain medications also induce RESLES. Besides the use and withdrawal of antiepileptic medications, such as oxcarbazepine ( 5 , 33 ), levetiracetam ( 34 ), and phenytoin ( 35 ), psychiatric medication use, including olanzapine ( 7 ), and glufosinate ammonium poisoning ( 15 ) can also purportedly induce RESLES. It remains unclear, however, whether suspected seizures or valproate, which was used after a transient loss of conscious, may have induced RESLES in case 12.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Reversible Splenial Lesion Syndrome with Some Novel Causes and Clinical Manifestations

Hodes

Zheng

et al. 2020

Intern. Med.

View full text Add to dashboard Cite

Objective Reversible splenial lesion syndrome (RESLES) is a clinical radiological syndrome characterized by a reversible lesion of the splenium of the corpus callosum with a decreased apparent diffusion coefficient (ADC) value. The clinical manifestations of RESLES are diverse. Methods Fifteen cases of adult RESLES patients (10 males and 5 females) were retrospectively selected from the radiology system using the key word "corpus callosum" at a university-affiliated tertiary care hospital between May 1, 2015 and December 31, 2019. The possible precipitating factors, clinicoradiological findings and modified Rankin Scale (mRS) on follow-up were then analyzed. Results The patient ages ranged from 22 to 53 years old. The mean age was 34 years old. The most common neurological symptoms included headache (3/15), dizziness (3/15), first onset of seizure (3/15), paroxysmal blurred vision (2/15), vertigo (2/15), amnesia (2/15), and confused consciousness without seizure (2/15), followed by drowsiness (1/15), paresthesia (1/15), dysmetria (1/15) and dysarthria (1/15). The precipitating factors included infection, seizure, anti-epileptic treatment with levetiracetam, carbamazepine, valproate, hyperglycemia, hypoglycemia, cerebral venous sinus thrombosis, and rabies vaccine injection prior to the onset of RESLES. All cases were carefully followed up and had excellent prognoses. Conclusion RESLES manifests as variety of symptoms with less specificity and precipitating factors. Paroxysmal blurred vision may be a relatively specific symptom of RESLES. Levetiracetam, carbamazepine or valproate could be the cause of RESLES, exposure to the rabies vaccine could be another predisposing factors for RESLES as well. RESLES type 1 was therefore found to be highly "reversible" with an excellent prognosis.

show abstract

“…Some antiepileptic drugs can reportedly cause CLOCCs; for example, carbamazepine can interact with arginine-vasopressin and therein influence fluid balance systems [7, 8]. However, only 1 CLOCC case has been reported that was caused by rapid withdrawal of levetiracetam, which is primarily used as a perioperative antiepileptic drug in our study [9]. This prejudicial drug usage might affect the result and thus we could not identify the correlation between antiepileptic drugs and CLOCCs in SAH patients.…”

Section: Discussion/conclusionmentioning

confidence: 85%

Clinical Significance of Cytotoxic Lesions of the Corpus Callosum in Subarachnoid Hemorrhage Patients: A Retrospective Analysis

2021

View full text Add to dashboard Cite

Introduction: Cytotoxic lesions of the corpus callosum are secondary lesions induced by significant increases in cytokine levels in the brain and are associated with subarachnoid hemorrhage (SAH). However, their clinical significance in SAH patients remains unclear. Methods: We retrospectively analyzed SAH patients who were treated in our hospital and evaluated between-group differences in the backgrounds, clinical findings, and outcomes between SAH patients who developed cytotoxic lesions of the corpus callosum and those who did not. We further compared patients who achieved good outcomes with those who had poor outcomes. Multivariate logistic regression analysis was used to identify risk factors for poor clinical outcomes. Results: We analyzed 159 SAH patients; 17 patients (10.7%) had cytotoxic lesions of the corpus callosum. Patients with cytotoxic lesions of the corpus callosum were more likely to be in a severe condition (World Federation of Neurosurgical Societies grading IV-V: odds ratio [OR], 4.53; 95% confidence interval [95% CI]: 1.60–12.84; p = 0.0042) and have an intraventricular (OR, 5.98; 95% CI: 1.32–27.13; p = 0.0054) or an intraparenchymal hematoma (OR, 3.62; 95% CI: 1.25–10.45; p = 0.023). Patients with cytotoxic lesions of the corpus callosum had a greater propensity of a poor outcome 3 months after onset (modified Rankin Scale score 0–2: OR, 0.22; 95% CI: 0.07–0.66; p = 0.0043). Multivariate analysis confirmed that cytotoxic lesions of the corpus callosum increased the risk of a poor outcome (OR, 4.39; 95% CI: 1.06–18.1; p = 0.037). Discussion/Conclusions: The development of cytotoxic lesions of the corpus callosum may be related to the extent of hematomas in SAH patients. Although they are usually reversible lesions, the development of cytotoxic lesions of the corpus callosum may be a predictor of poor outcomes in SAH patients.

show abstract

Transient lesions of the splenium of the corpus callosum following rapid withdrawal of levetiracetam

Cited by 6 publications

References 8 publications

Rotavirus-associated seizures and reversible corpus callosum lesion

Rotavirus-associated seizures and reversible corpus callosum lesion

Reversible Splenial Lesion Syndrome with Some Novel Causes and Clinical Manifestations

Clinical Significance of Cytotoxic Lesions of the Corpus Callosum in Subarachnoid Hemorrhage Patients: A Retrospective Analysis

Contact Info

Product

Resources

About